Regeneron Reports Second Quarter 2026 Financial and Operating Results

{
  "signal_id": "62ba4536-0dc5-49d7-2581-dde58669188c",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-07-30T10:30:00+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/07/30/3335868/0/en/Regeneron-Reports-Second-Quarter-2026-Financial-and-Operating-Results.html",
    "title": "Regeneron Reports Second Quarter 2026 Financial and Operating Results",
    "excerpt": "TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced financial results for the second quarter of 2026 and provided a business update. \"Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline,\" said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. \"Of note, global Dupixent, global Libtayo, and U.S. EYLEA HD net product sales increased by 38%, 30%, and 52%, respectively, compared to the second quarter of 2025. With approximately 50 clinical assets, we remain focused on translating our science into even more successful new medicines across a broad array of diseases.\" Financial Highlights \"Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures,\" said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron. \"By the end of the second quarter, we had fully repaid the Sanofi Development Balance, which represented the outstanding amount due to Sanofi for their funding of prior collaboration development activities. The repayment of this obligation will drive a meaningful step-up in...",
    "summary": "Regeneron Pharmaceuticals reported a 17% increase in revenues for the second quarter of 2026.",
    "location": "Tarrytown, NY, USA",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1",
    "confidence": 0.9,
    "published_at": "2026-07-30T10:30:00Z",
    "location_data": [
      {
        "city": "Tarrytown",
        "state": "New York",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "\"Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures,\" said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron."
  }
}

curl https://signals.autobound.ai/v1/signals/62ba4536-0dc5-49d7-2581-dde58669188c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'